930 related articles for article (PubMed ID: 10873065)
21. Enhancement of tumor radioresponse by combined treatment with gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, is accompanied by inhibition of DNA damage repair and cell growth in oral cancer.
Shintani S; Li C; Mihara M; Terakado N; Yano J; Nakashiro K; Hamakawa H
Int J Cancer; 2003 Dec; 107(6):1030-7. PubMed ID: 14601066
[TBL] [Abstract][Full Text] [Related]
22. Enhanced response to C225 of A431 tumor xenografts growing in irradiated tumor bed.
Riesterer O; Mason KA; Raju U; Yang Q; Wang L; Hittelman WN; Ang KK; Milas L
Radiother Oncol; 2009 Sep; 92(3):383-7. PubMed ID: 19695723
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of radiation-induced EGFR nuclear import by C225 (Cetuximab) suppresses DNA-PK activity.
Dittmann K; Mayer C; Rodemann HP
Radiother Oncol; 2005 Aug; 76(2):157-61. PubMed ID: 16024112
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.
Ciardiello F; Caputo R; Bianco R; Damiano V; Fontanini G; Cuccato S; De Placido S; Bianco AR; Tortora G
Clin Cancer Res; 2001 May; 7(5):1459-65. PubMed ID: 11350918
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin.
Lamszus K; Brockmann MA; Eckerich C; Bohlen P; May C; Mangold U; Fillbrandt R; Westphal M
Clin Cancer Res; 2005 Jul; 11(13):4934-40. PubMed ID: 16000592
[TBL] [Abstract][Full Text] [Related]
26. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.
Petit AM; Rak J; Hung MC; Rockwell P; Goldstein N; Fendly B; Kerbel RS
Am J Pathol; 1997 Dec; 151(6):1523-30. PubMed ID: 9403702
[TBL] [Abstract][Full Text] [Related]
27. Insulin-like growth factor receptor as a therapeutic target in head and neck cancer.
Barnes CJ; Ohshiro K; Rayala SK; El-Naggar AK; Kumar R
Clin Cancer Res; 2007 Jul; 13(14):4291-9. PubMed ID: 17634559
[TBL] [Abstract][Full Text] [Related]
28. Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model.
Zhang X; Chen ZG; Choe MS; Lin Y; Sun SY; Wieand HS; Shin HJ; Chen A; Khuri FR; Shin DM
Clin Cancer Res; 2005 Sep; 11(17):6261-9. PubMed ID: 16144930
[TBL] [Abstract][Full Text] [Related]
29. Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-kappaB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines.
Bancroft CC; Chen Z; Yeh J; Sunwoo JB; Yeh NT; Jackson S; Jackson C; Van Waes C
Int J Cancer; 2002 Jun; 99(4):538-48. PubMed ID: 11992543
[TBL] [Abstract][Full Text] [Related]
30. Enhanced antiangiogenic therapy of squamous cell carcinoma by combined endostatin and epidermal growth factor receptor-antisense therapy.
Li M; Ye C; Feng C; Riedel F; Liu X; Zeng Q; Grandis JR
Clin Cancer Res; 2002 Nov; 8(11):3570-8. PubMed ID: 12429648
[TBL] [Abstract][Full Text] [Related]
31. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer.
Shin DM; Donato NJ; Perez-Soler R; Shin HJ; Wu JY; Zhang P; Lawhorn K; Khuri FR; Glisson BS; Myers J; Clayman G; Pfister D; Falcey J; Waksal H; Mendelsohn J; Hong WK
Clin Cancer Res; 2001 May; 7(5):1204-13. PubMed ID: 11350885
[TBL] [Abstract][Full Text] [Related]
32. Decreased repopulation as well as increased reoxygenation contribute to the improvement in local control after targeting of the EGFR by C225 during fractionated irradiation.
Krause M; Ostermann G; Petersen C; Yaromina A; Hessel F; Harstrick A; van der Kogel AJ; Thames HD; Baumann M
Radiother Oncol; 2005 Aug; 76(2):162-7. PubMed ID: 16024114
[TBL] [Abstract][Full Text] [Related]
33. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer.
Herbst RS; Hong WK
Semin Oncol; 2002 Oct; 29(5 Suppl 14):18-30. PubMed ID: 12422310
[TBL] [Abstract][Full Text] [Related]
34. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.
Sok JC; Coppelli FM; Thomas SM; Lango MN; Xi S; Hunt JL; Freilino ML; Graner MW; Wikstrand CJ; Bigner DD; Gooding WE; Furnari FB; Grandis JR
Clin Cancer Res; 2006 Sep; 12(17):5064-73. PubMed ID: 16951222
[TBL] [Abstract][Full Text] [Related]
35. Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation.
Saleh MN; Raisch KP; Stackhouse MA; Grizzle WE; Bonner JA; Mayo MS; Kim HG; Meredith RF; Wheeler RH; Buchsbaum DJ
Cancer Biother Radiopharm; 1999 Dec; 14(6):451-63. PubMed ID: 10850332
[TBL] [Abstract][Full Text] [Related]
36. Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice.
Kim SJ; Uehara H; Karashima T; Shepherd DL; Killion JJ; Fidler IJ
Clin Cancer Res; 2003 Mar; 9(3):1200-10. PubMed ID: 12631626
[TBL] [Abstract][Full Text] [Related]
37. Angiogenesis and radiation response modulation after vascular endothelial growth factor receptor-2 (VEGFR2) blockade.
Li J; Huang S; Armstrong EA; Fowler JF; Harari PM
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1477-85. PubMed ID: 16029810
[TBL] [Abstract][Full Text] [Related]
38. C225 antiepidermal growth factor receptor antibody enhances the efficacy of docetaxel chemoradiotherapy.
Nakata E; Hunter N; Mason K; Fan Z; Ang KK; Milas L
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):1163-73. PubMed ID: 15234052
[TBL] [Abstract][Full Text] [Related]
39. Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck.
Chen Z; Zhang X; Li M; Wang Z; Wieand HS; Grandis JR; Shin DM
Clin Cancer Res; 2004 Sep; 10(17):5930-9. PubMed ID: 15355926
[TBL] [Abstract][Full Text] [Related]
40. Enhancement of radiosensitivity in head and neck cancer cells by ZD1839 ('IRESSA'), a selective epidermal growth factor receptor tyrosine kinase inhibitor.
Shintani S; Kiyota A; Mihara M; Sumida T; Kayahara H; Nakashiro K; Hamakawa H
Am J Clin Oncol; 2003 Oct; 26(5):e150-6. PubMed ID: 14528090
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
